Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0615 ET – Merck KGaA expects its 2024 sales target to come in ...

Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Merck, which previously predicted 2024 sales of between ... data analyses and commentary from our global network of life ...

The global protein expression market is expected to reach USD 4.82 billion in 2029 from USD 3.41 billion in 2024 at a CAGR of ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...

Merck KGaA reported a 16.6% decline in contract manufacturing due to an unrepeated Covid-19 contract, though overall life ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...